These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21916789)

  • 1. Agomelatine for the treatment of major depressive disorder.
    Carney RM; Shelton RC
    Expert Opin Pharmacother; 2011 Oct; 12(15):2411-9. PubMed ID: 21916789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agomelatine targets a range of major depressive disorder symptoms.
    Dubocovich ML
    Curr Opin Investig Drugs; 2006 Jul; 7(7):670-80. PubMed ID: 16869122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism, efficacy, and tolerability profile of agomelatine.
    MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agomelatine: AGO 178, AGO178, S 20098.
    Drugs R D; 2008; 9(3):177-83. PubMed ID: 18457470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
    de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ
    Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agomelatine for major depressive episodes.
    Drug Ther Bull; 2010 Aug; 48(8):93-6. PubMed ID: 20685900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Agomelatine].
    Tessmer M
    Med Monatsschr Pharm; 2009 Aug; 32(8):282-8. PubMed ID: 19777735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine, a melatonin agonist with antidepressant properties.
    Dubovsky SL; Warren C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
    Olié JP; Kasper S
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agomelatine in depression.
    Smeraldi E; Delmonte D
    Expert Opin Drug Saf; 2013 Nov; 12(6):873-80. PubMed ID: 24033095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A benefit-risk assessment of agomelatine in the treatment of major depression.
    Howland RH
    Drug Saf; 2011 Sep; 34(9):709-31. PubMed ID: 21830835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agomelatine: a preliminary review of a new antidepressant.
    Zupancic M; Guilleminault C
    CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Agomelatine: the first "melatoninergic" antidepressant].
    Bánki MC
    Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
    CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agomelatine: a novel pharmacological approach to treating depression.
    Owen RT
    Drugs Today (Barc); 2009 Aug; 45(8):599-608. PubMed ID: 19927226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of antidepressants in clinical practice: focus on agomelatine.
    McAllister-Williams RH; Baldwin DS; Haddad PM; Bazire S
    Hum Psychopharmacol; 2010 Mar; 25(2):95-102. PubMed ID: 20196187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
    Singh SP; Singh V; Kar N
    Int J Neuropsychopharmacol; 2012 Apr; 15(3):417-28. PubMed ID: 21859514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine: efficacy at each phase of antidepressant treatment.
    Kennedy SH
    CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.